Blood is mandatory to maintain adequate circulation, providing nutrients, and removing waste from the brain, vital organs, and tissues. Hemorrhage is the loss of blood components from the cardiovascular system. Hemorrhagic shock occurs when this blood loss leads to inadequate tissue oxygenation. Hemorrhage secondary to traumatic injury is the leading cause of death of Americans from one to 46 years of age. The Stop the Bleed campaign was first launched in 2013. This educational program aims to reduce the morbidity and mortality associated with hemorrhage secondary to traumatic injury.
Significant improvements in clinical outcomes can be made by transferring knowledge from the military to civilian medicine. This article reviews some of the latest science and lessons learned to improve the care of a hemorrhaging patient.
In 2000, the World Health Organization (WHO) estimated that injury resulted in 9% of the global mortality and 12% of the worldwide disease burden. Worldwide, severe trauma results in the death of over 5 million persons annually and is projected to surpass 8 million annually by the year 2020. Hemorrhage accounts for approximately 35% of the mortality from these traumatic injuries, second only to central nervous system (CNS) injury. Up to half of the deaths resulting from hemorrhage occur before reaching definitive care. Violence is the leading cause of these injuries and traffic collisions are second. In 2015, the National Trauma Institute estimated that in the civilian arena, "severe bleeding accounts for greater than 35% of pre-hospital deaths and nearly 40% of deaths within the first 24 hours of injury." Coagulopathy affects 25% of these injured patients. This results from "hemorrhage, hemodilution, hypothermia, and acidosis."
Ninety percent of the mortality caused by these injuries occur in low and middle-income countries. Half of those affected are between the ages of 15 and 44 and males are affected twice as often as females. In 2003, injuries were the third leading cause of death overall in the United States and the leading cause of death for those between the ages of 1 and 46. These injuries represented 30% of the years of potential life lost before age 65 and accounted for almost 10% of the national expenditure on healthcare. Despite advances in medicine and prehospital care, these numbers have not improved significantly. In 2008, the WHO estimated that over 16,000 people died daily from traumatic injuries.
There are 3 main categories of bleeding. Lacerations, punctures, and amputations can result in arterial bleeding which is characterized by spurting, or pulsatile, bright red blood. These wounds can also result in venous bleeding. Venous bleeding is characterized by flowing, dark red blood. This flow can be steady but lacks the force of the arterial system. Capillary bleeding is a much more common form of bleeding that results from injury to the integumentary system. Capillary bleeding is characterized by oozing blood from the damaged area. Capillary bleeding can be the most painful, but the easiest to control due to its superficial nature.
A weak or absent radial pulse and a systolic blood pressure below 90 mm Hg are 2 indicators of shock in the hemorrhagic patient. Similarly, pale or ashen skin and fast, thready, central pulses are signs of hypovolemia. A capillary refill time of more than 2 seconds also indicates poor perfusion which in the presence of significant trauma can indicate hypovolemia. The American College of Surgeons developed a classification system for Advanced Trauma Life Support to use some of these parameters to grade the progression of shock. They define class I shock as the loss of less than 15% of total blood volume and includes mostly normal vital signs. Class II includes a blood loss of 15% to 30% and shows a slight deviation from normal vital signs. The vital sign deviation from normal increases in Class III, where blood loss is between 31% and 40%. Finally, Class IV includes patients with losses of greater than 40% of total blood volume, which can lead to altered mental status, hypotension, tachycardia, and tachypnea. In recent years several studies questioned the consistency of this classification system. These studies found base deficit (BD) to be a consistent measurement that could aid in the classification of hemorrhage. ATLS was updated to include BD as a parameter of the existing hemorrhage classification system.
The physical exam often provides the most valuable information regarding blood loss; however, many lab tests can assess the hemorrhaging patient. The lethal triad is comprised of coagulopathy, hypothermia, and acidosis. Coagulopathy of trauma is a significant risk factor for hemorrhagic death. Viscoelastic whole blood assays such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM) quantify clotting kinetics and may be superior to conventional coagulation assays given their potential for tailored treatment plans. Similar to TEG and ROTEM, prothrombin time (PT), international standardized ratio (INR), activated partial thromboplastin time (PTT), fibrinogen, and platelets can be used to detect coagulopathy. Furthermore, serum lactate and base deficit can be used to monitor the extent of tissue hypoperfusion. Single hematocrit measurements are not recommended for monitoring acute blood loss.
Regarding hemorrhage control, the location of the bleeding is critically important. There are 2 major categories to consider: compressible and non-compressible. Any obvious bleeding in a compressible area should be treated with direct digital pressure first. Should direct pressure fail, a tourniquet should be applied. Use of specific pressure points to control bleeding is no longer recommended based on scientific literature which has demonstrated collateral circulation defeating it. While the Stop the Bleed campaign promotes placing all tourniquets as proximal as possible on a wounded extremity in a "high or die" mentality, this strategy is not universally recommended. The Committee on Tactical Combat Casualty Care (CoTCCC) states that this should only be performed when the scene is still unsafe during care under fire. Once a scene has been secured, the CoTCCC recommends a new tourniquet be placed directly on the skin, 2 to 3 inches proximal to the wound and the more proximal tourniquet loosened. If bleeding in any extremity continues after placing one tourniquet, a second should be placed side-by-side to the first. A study of wounded service members and civilians from the recent wars in Iraq and Afghanistan demonstrated a 92% survival rate of casualties who had tourniquets applied to extremity injuries. However, no casualties survived after suffering an uncontrolled extremity hemorrhage in which no tourniquet was used. Of the 308 limbs that had tourniquets applied, there were only 10 nerve palsies noted (3.2%), with 4 at the level of the tourniquet. Most of these reported palsies resolved within hours and not a single amputation was performed as a result of tourniquet use. Other reports note that tourniquets have been left in place for up to 6 hours without loss of the affected limb.
Non-compressible hemorrhage often takes the form of truncal (thoraco-abdominopelvic) or junctional wounds. These wounds account for 21% of recent combat deaths. Junctional areas, where an extremity meets the trunk, include the groin above the inguinal ligament, the gluteals and pelvis, the perineum, the axilla, and the base of the neck. Throughout history, several surgeons have made their own tourniquet devices and successfully used them on large arteries. However, these devices were used by experienced surgeons on patients who were not moving and did not need to be moved. In recent years, several truncal tourniquets have been developed for field use, including the Combat Ready Clamp (CRoC), the Junctional Emergency Treatment Tool (JETT), and the SAM Junctional Tourniquet (SJT). One recent study demonstrates their ease of deployment but shows the need for improvement when transporting patients who have a junctional tourniquet applied. Further research shows that a knee with significant force applied just superior to the umbilicus, or just inferior and lateral to it may stop or slow hemorrhage from the aorta, iliac, or femoral arteries while these devices are applied.
In the early 2000s, hemostatic agents were being pressed into development. A chitosan-based dressing and a zeolite mineral powder were the first approved by the US military. These hemostatic agents were most useful for non-compressible wounds. Chitosan-based dressings worked by adhering to hemorrhaging tissues and sealing vessels; however, its efficacy diminished over time. The zeolite mineral powder's mechanism of action is based on rapid water absorption, concentrating clotting factors, and cells and increasing clot formation. A dry fibrin sealant dressing was developed using concentrated fibrinogen and thrombin from donated human plasma. However, its expense and increased testing requirements prevented its widespread use. Similarly, a chitin-based dressing was created, but its cost far exceeds other equally effective agents. One product, made of smectite minerals, was developed to both concentrate clotting elements by desiccation and activate the intrinsic coagulation pathway. While the products made of smectite minerals proved to be highly effective at hemostasis, studies showed that it caused thrombi to form that could migrate throughout the circulatory system, resulting in devastating complications. A surgical gauze impregnated with kaolin and aluminum silicate, also proved to be effective at activating the intrinsic pathway and facilitating hemostasis without known side effects. Following these studies, the CoTCCC decided in 2015 to recommend the surgical gauze impregnated with kaolin and aluminum silicate as the "hemostatic agent of choice." Two chitosan-based dressings, were recommended as alternatives to the surgical gauze impregnated with kaolin and aluminum silicate. Lastly, a syringe which injects expandable sponges into the wound tract to create a physical barrier and pressure inside the cavity proved highly effective against narrow but deep penetrating wounds to some regions.
All 3 gauze-type hemostatic agents recommended by CoTCCC should be placed on or packed into wounds and followed by at least 3 minutes of direct pressure. During this time, junctional tourniquets should be applied to sites amenable to their use. The CoTCCC also recommends that limb and junctional tourniquets be converted to a hemostatic or pressure dressing if all 3 of the following criteria are met: "the casualty is not in shock; it is possible to monitor the wound closely for bleeding, and the tourniquet is not being used to control bleeding from an amputated extremity." This should be completed within 2 hours of tourniquet placement whenever possible. Furthermore, the CoTCCC recommends that tourniquets in place greater than 6 hours not be removed unless the patient is under close monitoring with lab capabilities.
Several other physical actions can be performed to save the life of a patient hemorrhaging from a non-compressible area. Bleeding control of the abdomen can be accomplished by packing, to include hemostatic agents, but requires surgical capabilities. Pelvic fractures should be stabilized with a pelvic binder or pelvic C-Clamp to control bleeding until the patient reaches the operating room. Definitive treatment of abdominopelvic bleeding often requires surgical intervention. If a patient continues to exsanguinate despite other efforts, a resuscitative thoracotomy (RT) with aortic cross-clamping can be performed. Similarly, angiographic embolization through Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) can be used to stop uncontrolled bleeding not amenable to other means. Recent studies suggest no overall difference in mortality between RT and REBOA. For both procedures, the ischemia caused by occluding the aorta is one of the most significant complications.
Several medications can be given to patients to promote and enhance their ability to form clots. Tranexamic acid (TXA) is a lysine derivative that blocks the activation of plasmin. Plasmin breaks down fibrin clots thereby inhibiting hemostasis. TXA has demonstrated improved mortality and decreased blood product requirements among trauma patients when given in the first 3 hours after injury. However, the use of TXA in urban areas with advanced prehospital and trauma systems has been questioned by several studies showing decreased efficacy. Since fibrinogen is one of the first clotting factors depleted following hemorrhage, several studies have focused on its use in the trauma patient. While it has shown decreased mortality in the short term, the 30-day mortality was not significantly different and more studies have been encouraged. Recombinant factor VIIa is another possible treatment for severe hemorrhage; however, it is not considered a first-line treatment. It is approved for use pre-operatively in patients with factor VII deficiency or hemophilia. Prothrombin complex concentrate (PCC) is another medication that deserves further study for hemorrhaging patients. Four-factor PCC consists of factors II, VII, IX, and X and is used to reverse vitamin K antagonists as well as treat congenital coagulation disorders.
Following the success of the Surviving Sepsis Campaign, the STOP the Bleeding campaign was launched in Europe in 2013. The goal of the campaign is to "reduce the number of patients who die within 24 hours after arrival in hospital due to exsanguination by at least 20% within five years." Knowing that over 5 million people die annually from traumatic injuries and that a third of trauma patients present to the hospital with a coagulopathy, they aim to support hemostatic resuscitation measures. The campaign focuses on providing guidelines to facilitate the early recognition and treatment of hemorrhage and coagulopathy. The acronym STOP stands for Search, Treat, Observe and Prevent. In 2015, the White House launched the Stop the Bleed campaign in the United States. This campaign has similar objectives to its European predecessor and also provides layperson medical training. The US Department of Homeland Security hosts the Stop the Bleed website.
Improving outcomes in patients with hemorrhage starts the moment the patient is injured. Stop the Bleed campaigns, layperson aid, proper dispatch and timely response followed by rapid treatment and transport by EMS with early notification to the receiving hospital are paramount. (Level IV) The goal of the creation of trauma teams was to mobilize adequate resources, distribute the workload of assessments and procedures, and improve patient outcomes. While there are significant differences among what constitutes a trauma team, it is essential to have a surgeon and/or an emergency medicine physician, and an anesthetist available. Furthermore, having a designated Trauma Team Leader has been found to improve patient outcomes. (Level IV)